A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease
Dementia and Geriatric Cognitive Disorders Extra · 29.09.2015 · 5 (3) · 361-374
DOI: 10.1159/000439269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dementia and Geriatric Cognitive Disorders Extra, online erschienen am 29.09.2015. Verfasst von Yu Nakamura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Faculty of Medicine, Kagawa University, Kagawa, Japan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Demenz
Abstract (Originalsprache)
Aim
To investigate whether 1-step titration of the rivastigmine patch (initiated at 5 cm2 and titrated to 10 cm2 after 4 weeks) is well tolerated in Japanese patients with Alzheimer's disease (AD) as compared to 3-step titration (initiated at 2.5 cm2 and titrated by 2.5 cm2 every 4 weeks to 10 cm2).
Methods
A 24-week, multicenter, randomized, double-blind study was conducted in Japan between July 2012 and May 2014. Patients with mild to moderate AD aged 50-85 years were randomized 1:1 to 1-step or 3-step titration of the rivastigmine once-daily patch. The primary endpoint was the proportion of patients with adverse events leading to discontinuation.
Results
Of 216 patients randomized, 215 (1-step, n = 107; 3-step, n = 108) were included in the safety analysis. The primary endpoint outcome was 15.0% in the 1-step group and 18.5% in the 3-step group. The observed treatment difference was −3.6% (95% confidence interval: −17.0, 9.6), falling within the prespecified acceptance range.
Conclusion
The tolerability of two different titration schemes was similar in Japanese patients with AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuropsychiatry, Faculty of Medicine, Kagawa University, Kagawa, Japan.
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Pharma K.K., Tokyo, Japan.
- Ono Pharmaceutical Co., Ltd., Osaka, Japan.
- Dementia Care Research and Training Center, Tokyo, Japan.
Zitieren
APA
Nakamura, Y., Strohmaier, C., Tamura, K., Kataoka, N., Nakano, M., Oda, S., Nishimura, K., & Homma, A. (2015). A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 5(3), 361-374. https://doi.org/10.1159/000439269
Vancouver
Nakamura Y, Strohmaier C, Tamura K, Kataoka N, Nakano M, Oda S, et al. A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra. 2015;5(3):361-374. doi:10.1159/000439269
BibTeX
@article{Nakamura2015,
author = {Nakamura, Yu and Strohmaier, Christine and Tamura, Kaoru and Kataoka, Naoko and Nakano, Masayuki and Oda, Shoichiro and Nishimura, Kazuma and Homma, Akira},
title = {A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease},
journal = {Dementia and Geriatric Cognitive Disorders Extra},
year = {2015},
volume = {5},
number = {3},
pages = {361--374},
doi = {10.1159/000439269}
}
EUVIMED